Pure Lithium and Saint-Gobain Ceramics Enter Into a Joint Development Agreement to Accelerate Production of Lithium-selective Membranes for Metal Extraction and Battery Applications
15.1.2025 18:11:00 CET | Business Wire | Press release
Pure Lithium Corporation, a Boston-based lithium metal battery technology company, announces a joint development agreement with Saint-Gobain Ceramics, a global leader in specialty ceramic materials. The joint development agreement will accelerate the production of Pure Lithium’s patent pending lithium selective, water-blocking membranes for lithium metal anode production from brine.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250115117089/en/
Additionally, Pure Lithium invented a flexible lithium conducting membrane for next-generation lithium metal battery applications, which will serve as both a solid electrolyte and separator in a lithium metal battery. Saint-Gobain Ceramics will also scale this technology.
Emilie Bodoin, Founder and CEO of Pure Lithium comments: “I am delighted to be scaling our technology with an industrial partner. Saint-Gobain Ceramics has world-class R&D expertise coupled with manufacturing and production capabilities. Their technical team is unique. I am proud of the Pure Lithium team for inventing and developing these high performance membranes. This partnership will accelerate our time to market, which is vital in the battery industry.”
“Saint-Gobain Ceramics teams are ready to co-develop with Pure Lithium innovative membranes to revolutionize the lithium extraction and battery markets. They can rely on our strong expertise in this segment and unique R&D capabilities. These solutions are key to supporting the electrical transition worldwide,” precised Nicolas Miègeville, CEO Saint-Gobain Ceramics.
About Saint-Gobain Ceramics
Worldwide leader in light and sustainable construction, Saint-Gobain designs, manufactures and distributes materials and services for the construction and industrial markets. Thanks to a leading-edge expertise in materials science and a strong capacity of innovation, Saint-Gobain Ceramics offers advanced ceramic and refractory materials to support customers in their decarbonization and circular economy journey. These solutions enable industry leaders and key innovators to meet the toughest application requirements in a broad range of industrial markets, such as glass, electric vehicles, lithium extraction, aerospace, semiconductors, and many others.
About Pure Lithium
Pure Lithium is a disruptive Boston-based lithium metal battery technology company led by inventor and lithium expert, CEO Emilie Bodoin, and world-renowned battery and metallurgical expert, MIT Emeritus Professor Donald R. Sadoway, as full-time CSO. The Company's novel Brine to Battery™ technology combines metal extraction and anode production, unlocking unconventional sources of lithium. The resulting pure lithium metal anode is the core component of our lithium metal vanadium oxide battery, a step-change improvement over today’s lithium-ion technology in cell performance, cost, and safety. Additionally, the battery is free of graphite, cobalt, nickel, and manganese. For more information, visit www.purelithium.io or email news@purelithium.io.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250115117089/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom